RLAY MEXC RealStocks
Own real RLAY shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-14 10:20:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Relay Therapeutics, Inc. (RLAY) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $18.10, with a market capitalization of $3.99B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.17 to $21.27. This page covers its latest market performance, valuation, price trends and company information.
$3.99B | |
$17.95 | |
$18.60 | |
$17.26 | |
$18.08 | |
1.22M | |
2.94M | |
-- | |
$21.27 | |
$6.17 | |
-- | |
-- |
Relay Therapeutics, Inc. (RLAY) last closed at $18.10 as of 2026-11-14 00:31:00, up 0.11% ($0.02) from the previous close of $18.08.
During the latest regular trading session, RLAY traded between $17.26 and $18.60, with a volume of 1.22M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Relay Therapeutics, Inc. (RLAY) moved from $17.00 to $18.10, representing a gain of 6.48% ($1.10).
The stock traded between $16.52 and $20.96 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 2.91 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 79.0%
RLAY is currently trading at $18.10, placing it 79.0% of the way from its 52-week low of $6.17 to its 52-week high of $21.27. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 218 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Relay Therapeutics, Inc. (RLAY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RLAY, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RLAY shares and USD.
RLAY Shares to USD
1.00 RLAY shares = 18.101 USD
Calculations are estimates based on the latest available price and are for reference only.